

June 2, 2016

**Parnell Pharmaceuticals Holdings Ltd.  
(PARN/Buy/USD\$1.64)**

*Sherry Grisewood, CFA*  
Managing Partner, Life Science Research  
561-208-2943  
sgrisewood@dawsonjames.com

**Parnell Executes: Announces First Contract Manufacturing Agreement**

Parnell has executed on its first contract manufacturing agreement to leverage excess capacity at its Australian cGMP sterile manufacturing facility. Parnell has announced that the Company and Merial, Sanofi's (SNY/\$41.14/Not rated) animal health division have entered into and commenced a Contract Manufacturing Agreement. The Agreement has a 10-year life and provides for Merial's purchase of certain sterile injectable pharmaceutical products under minimum annual purchase commitments over the life of the Agreement. Upon the receipt of the upfront establishment fee from Merial, Parnell will commence immediate production of product. Parnell estimates the total value of the agreement between USD\$7 million and USD\$20 million depending on volume of product purchased by Merial over the 10-year term.

Robert Joseph, President and CEO, was quoted in the press release as saying, "We are very pleased to announce the commencement of our first contract manufacturing agreement with a major multinational. Merial has a fantastic reputation in the industry and we are excited that Parnell will be supplying sterile injectable products from our state-of-the-art, FDA and EMA approved manufacturing facility. Our Business Development team has been pursuing contract manufacturing opportunities to leverage the 75% available capacity we have in our facility, and this agreement with Merial generates cash flows that will contribute to our goal of seeing our manufacturing division become a profit center for us in the future. We hope to announce further contract manufacturing deals in 2016."



Parnell's ability to manufacturer both its own products and capitalize on leveraging its manufacturing resources for contract manufacturing is an important differentiator from its competitors. We believe the Merial name brings substantial credibility to the state of Parnell's manufacturing facility and the Company's manufacturing expertise that should facilitate other such agreements. Investors reacted very positively to the news yesterday and we continue to believe the stock is undervalued. We rate PARN shares a **BUY**. SG

Morning Notes provide current information we believe might be noteworthy to investors regarding the subject companies. Morning Notes are not intended to be complete research reports. More detailed information concerning the rated companies referenced in this Note, including the full reports, basis for price targets and other disclosures, may be found at: [http://dawsonjames.com/research\\_coverage](http://dawsonjames.com/research_coverage).

### **Important Disclosures:**

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the profiled company. The Firm has not received investment banking compensation from the company (s) profiled in this report (PARN) and may seek compensation for investment banking services in the future from the profiled company (s). The Firm has not received other compensation from the profiled company(s) in the last 12 months.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of May 31, 2016, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company (s) of this report. The Firm, its officers, directors, analysts or employees may effect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the companies subject to this report. The Firm may effect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

### **Ratings Definitions:**

- 1) **Buy:** the analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** the analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** the analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Ratings Distribution	Company Coverage		Investment Banking	
	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	13	72%	9	69%
Market Perform (Neutral)	5	28%	4	80%
Market Underperform (Sell)	0	0%	0	0%
Total	18	100%	13	72%

### **Analyst Certification:**

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.